ANTAGONIC-STRESS SUPERIORITY VERSUS MECLOFENOXATE IN GERONTOPSYCHIATRY (ALZHEIMER-TYPE DEMENTIA)

A double blind, comparative, parallel and randomized clinical trial wa s used for evaluation of two nootropics with anti-aging actions: Meclo fenoxate (MF) and Antagonic-Stress (AS). Sixty-three old persons divid ed into 2 groups (average age: 68.6 and 70.8 years, respectively) with senile dementia of Alzheimer type (SDAT), of mild to moderate intensi ty (criteria of DSM-III-R, APA, 1987; and ICD-10, WHO, 1990) were trea ted with one of these nootropica. Baseline and final psychogeriatric s ymptomatology after three months of treatments were multiply assessed: psychogeriatric by Sandoz Clinical Assessment-Geriatric scale, Self-A ssessment Scale-Geriatric and their subscales; psychometric by Wechsle r Memory Scale and Wechsler Adult intelligence Scale. prolonged treatm ents with MF and AS significantly decreased the psychogeriatric scores in scales and subscales, improved the cognitive performance (attentio n, concentration, memory, performance IQ, full IQ) and diminshed the d eterioration index (ANOVA). Therapeutical effects of AS (a neurometabo lic complex containing MF) were significantly superior against MF alon e (ANCOVA). MF and AS actions are discussed in connection with the bra in cholinergic system, lipid peroxidation and free radical scavengers, deceleration of the aging rate, brain and erythrocyte lipofuscinolysi s, multiple anti-oxidant formula, multivitamin and multimineral supple mentation and with the superiority of multitherapy versus monotherapy in senile dementia and for improving the IQ and the maladaptative beha vior.